BACKGROUND: Chronic kidney disease (CKD) is an increasingly common condition, especially in older adults. CKD manifests differently in older versus younger patients, with a risk of death that far outweighs the risk of CKD progressing to the point that dialysis is required. Current CKD guidelines recommend a blood pressure target <130/80 mm Hg for all patients with CKD; however, it is unknown how lower versus higher baseline blood pressures may affect older adults with CKD. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Older patients (aged ≥ 75 years) with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m(2)) in a community-based health maintenance organization. PREDICTOR: Baseline systolic blood pressure (SBP) < 130, 130-160 (reference group), and > 160 mm Hg. OUTCOMES: Participants were followed up for 5 years to examine rates of mortality (primary outcome) and cardiovascular disease hospitalizations (secondary outcome). RESULTS: At baseline, 3,099 participants (38.5%) had SBP < 130 mm Hg, 3,772 (46.9%) had SBP of 131-160 mm Hg, and 1,171 (14.6%) had SBP >160 mm Hg. A total of 3,734 (46.4%) died and 2,881 (35.8%) were hospitalized. Adjusted HRs for mortality in the groups with SBP < 130 and > 160 mm Hg were 1.22 (95% CI, 1.11-1.34) and 1.06 (95% CI, 0.93-1.22), respectively. Adjusted HRs for cardiovascular hospitalization in these groups were 1.10 (95% CI, 0.99-1.23) and 1.26 (95% CI, 1.09-1.45), respectively. LIMITATIONS: Although causality should not be inferred from this retrospective analysis, results from this study can generate hypotheses for future randomized controlled trials to investigate the relationship between blood pressure and outcomes in older patients with CKD. CONCLUSIONS: Our study suggests that lower baseline SBP (≤ 130 mm Hg) may predict poorer outcomes in terms of both mortality and cardiovascular hospitalizations in older adults with CKD. Conversely, higher baseline SBP (> 160 mm Hg) may predict increased risk of cardiovascular hospitalizations, but does not predict mortality. Clinical trials are required to test this hypothesis.
BACKGROUND:Chronic kidney disease (CKD) is an increasingly common condition, especially in older adults. CKD manifests differently in older versus younger patients, with a risk of death that far outweighs the risk of CKD progressing to the point that dialysis is required. Current CKD guidelines recommend a blood pressure target <130/80 mm Hg for all patients with CKD; however, it is unknown how lower versus higher baseline blood pressures may affect older adults with CKD. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Older patients (aged ≥ 75 years) with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m(2)) in a community-based health maintenance organization. PREDICTOR: Baseline systolic blood pressure (SBP) < 130, 130-160 (reference group), and > 160 mm Hg. OUTCOMES: Participants were followed up for 5 years to examine rates of mortality (primary outcome) and cardiovascular disease hospitalizations (secondary outcome). RESULTS: At baseline, 3,099 participants (38.5%) had SBP < 130 mm Hg, 3,772 (46.9%) had SBP of 131-160 mm Hg, and 1,171 (14.6%) had SBP >160 mm Hg. A total of 3,734 (46.4%) died and 2,881 (35.8%) were hospitalized. Adjusted HRs for mortality in the groups with SBP < 130 and > 160 mm Hg were 1.22 (95% CI, 1.11-1.34) and 1.06 (95% CI, 0.93-1.22), respectively. Adjusted HRs for cardiovascular hospitalization in these groups were 1.10 (95% CI, 0.99-1.23) and 1.26 (95% CI, 1.09-1.45), respectively. LIMITATIONS: Although causality should not be inferred from this retrospective analysis, results from this study can generate hypotheses for future randomized controlled trials to investigate the relationship between blood pressure and outcomes in older patients with CKD. CONCLUSIONS: Our study suggests that lower baseline SBP (≤ 130 mm Hg) may predict poorer outcomes in terms of both mortality and cardiovascular hospitalizations in older adults with CKD. Conversely, higher baseline SBP (> 160 mm Hg) may predict increased risk of cardiovascular hospitalizations, but does not predict mortality. Clinical trials are required to test this hypothesis.
Authors: V Vaccarino; A K Berger; J Abramson; H R Black; J F Setaro; J A Davey; H M Krumholz Journal: Am J Cardiol Date: 2001-11-01 Impact factor: 2.778
Authors: Jessica W Weiss; Dawn Peters; Xiuhai Yang; Amanda Petrik; David H Smith; Eric S Johnson; Micah L Thorp; Cynthia Morris; Ann M O'Hare Journal: Clin J Am Soc Nephrol Date: 2015-08-14 Impact factor: 8.237
Authors: Shyamal Palit; Michel Chonchol; Alfred K Cheung; James Kaufman; Gerard Smits; Jessica Kendrick Journal: Clin J Am Soc Nephrol Date: 2015-05-15 Impact factor: 8.237
Authors: Sankar D Navaneethan; Jesse D Schold; Stacey E Jolly; Susana Arrigain; Matthew F Blum; Wolfgang C Winkelmayer; Joseph V Nally Journal: Kidney Int Date: 2017-07-24 Impact factor: 10.612
Authors: Bakhtawar K Mahmoodi; Caroline S Fox; Brad C Astor; Robert G Nelson; Kunihiro Matsushita; Josef Coresh Journal: Lancet Date: 2013-02-16 Impact factor: 79.321
Authors: Ann M O'Hare; John R Hotchkiss; Manjula Kurella Tamura; Eric B Larson; Brenda R Hemmelgarn; Adam Batten; Thy P Do; Kenneth E Covinsky Journal: JAMA Intern Med Date: 2014-03 Impact factor: 21.873
Authors: Nisha Bansal; Charles E McCulloch; Feng Lin; Cassianne Robinson-Cohen; Mahboob Rahman; John W Kusek; Amanda H Anderson; Dawei Xie; Raymond R Townsend; Claudia M Lora; Jackson Wright; Alan S Go; Akinlolu Ojo; Arnold Alper; Eva Lustigova; Magda Cuevas; Radhakrishna Kallem; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-10-04 Impact factor: 10.612
Authors: Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor Journal: Lancet Date: 2012-09-24 Impact factor: 79.321